Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 12000 | $17.86 - $18.48 | $214,987 |
| 2024-04-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2024-04-29 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 3250 | $16.97 - $16.97 | $55,164 |
| 2024-04-29 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 3250 | $2.48 - $2.48 | $8,060 |
| 2024-04-25 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 12000 | $16.89 - $16.89 | $202,700 |
| 2024-04-25 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
S | Common Stock | D | 17500 | $25.03 - $25.03 | $438,098 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
M | Common Stock | A | 14903 | $2.48 - $2.48 | $36,959 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 30000 | $25.04 - $25.04 | $751,332 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
M | Common Stock | A | 30000 | $1.12 - $1.12 | $33,600 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 47709 | $25.04 - $25.04 | $1,194,700 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
M | Common Stock | A | 47709 | $1.12 - $1.12 | $53,434 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 14000 | $23.88 - $25.04 | $346,148 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 14000 | $2.48 - $2.48 | $34,720 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 6964 | $19.94 - $25.03 | $167,886 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Collins Helen Louise
(CHIEF MEDICAL OFFICER) |
S | Common Stock | D | 20000 | $25.07 - $25.07 | $501,477 |
| 2024-04-11 | Enliven Therapeutics, Inc. | Collins Helen Louise
(CHIEF MEDICAL OFFICER) |
M | Common Stock | A | 20000 | $2.48 - $2.48 | $49,600 |
| 2024-04-10 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
S | Common Stock | D | 67000 | $21.01 - $25.21 | $1,564,810 |
| 2024-04-10 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
M | Common Stock | A | 67000 | $12.60 - $19.68 | $876,626 |
| 2024-04-08 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
S | Common Stock | D | 4875 | $18.50 - $19.40 | $90,686 |
| 2024-04-04 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
S | Common Stock | D | 3485 | $19.15 - $19.15 | $66,729 |
| 2024-04-04 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
M | Common Stock | A | 3485 | $12.60 - $12.60 | $43,911 |
| 2024-04-01 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
S | Common Stock | D | 3237 | $19.08 - $19.08 | $61,758 |
| 2024-04-01 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
M | Common Stock | A | 3237 | $5.52 - $12.60 | $18,533 |
| 2024-04-01 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 12000 | $17.72 - $19.36 | $223,144 |
| 2024-04-01 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2024-03-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 3250 | $18.22 - $18.72 | $59,301 |
| 2024-03-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 3250 | $2.48 - $2.48 | $8,060 |
| 2024-03-25 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
S | Common Stock | D | 12000 | $17.17 - $18.16 | $210,660 |
| 2024-03-25 | Enliven Therapeutics, Inc. | Kintz Samuel
(PRESIDENT AND CEO) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2024-03-20 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
S | Common Stock | D | 13278 | $19.16 - $19.16 | $254,462 |
| 2024-03-20 | Enliven Therapeutics, Inc. | Ballal Rahul D.
(Director) |
M | Common Stock | A | 13278 | $5.52 - $5.52 | $73,294 |
| 2024-03-19 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1270 | $14.50 - $14.50 | $18,418 |
| 2024-03-06 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
S | Common Stock | D | 4875 | $15.64 - $15.64 | $76,238 |
| 2024-02-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 12000 | $16.30 - $17.09 | $197,005 |
| 2024-02-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2024-02-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 3250 | $16.97 - $16.97 | $55,162 |
| 2024-02-27 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 3250 | $2.48 - $2.48 | $8,060 |
| 2024-02-15 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1270 | $17.42 - $17.42 | $22,117 |
| 2024-02-06 | Enliven Therapeutics, Inc. | Patel Anish
(CHIEF OPERATING OFFICER) |
S | Common Stock | D | 4875 | $15.11 - $15.11 | $73,658 |
| 2024-01-30 | Enliven Therapeutics, Inc. | Heyman Richard A.
(Director) |
S | Common Stock | D | 1270 | $16.41 - $16.41 | $20,839 |
| 2024-01-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 12000 | $15.85 - $15.85 | $190,256 |
| 2024-01-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(CHIEF SCIENTIFIC OFFICER) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2024-01-29 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 3250 | $15.81 - $15.81 | $51,388 |
| 2024-01-29 | Enliven Therapeutics, Inc. | Hohl Benjamin
(CHIEF FINANCIAL OFFICER) |
M | Common Stock | A | 3250 | $2.48 - $2.48 | $8,060 |
| 2024-01-25 | Enliven Therapeutics, Inc. | Kintz Samuel
(President and CEO) |
S | Common Stock | D | 12000 | $14.94 - $15.89 | $188,229 |
| 2024-01-25 | Enliven Therapeutics, Inc. | Kintz Samuel
(President and CEO) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2024-01-22 | Enliven Therapeutics, Inc. | Patel Anish
(Chief Operating Officer) |
S | Common Stock | D | 4875 | $15.13 - $15.13 | $73,783 |
| 2023-12-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(Chief Scientific Officer) |
S | Common Stock | D | 12000 | $14.13 - $14.78 | $171,380 |
| 2023-12-29 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(Chief Scientific Officer) |
M | Common Stock | A | 12000 | $1.12 - $1.12 | $13,440 |
| 2023-12-28 | Enliven Therapeutics, Inc. | Patel Anish
(Chief Operating Officer) |
S | Common Stock | D | 13540 | $15.00 - $15.08 | $203,347 |
| 2023-12-28 | Enliven Therapeutics, Inc. | Hohl Benjamin
(Chief Financial Officer) |
M | Common Stock | A | 11870 | $2.48 - $2.48 | $29,436 |
| 2023-12-22 | Enliven Therapeutics, Inc. | Patel Anish
(Chief Operating Officer) |
S | Common Stock | D | 1085 | $15.01 - $15.03 | $16,305 |
| 2023-11-03 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(Chief Scientific Officer) |
S | Common Stock | D | 8546 | $13.08 - $13.08 | $111,750 |
| 2023-11-03 | Enliven Therapeutics, Inc. | Lyssikatos Joseph P
(Chief Scientific Officer) |
M | Common Stock | A | 8546 | $1.12 - $1.12 | $9,571 |
| 2023-11-03 | Enliven Therapeutics, Inc. | Kintz Samuel
(President and CEO) |
S | Common Stock | D | 8026 | $13.08 - $13.08 | $104,999 |
| 2023-11-03 | Enliven Therapeutics, Inc. | Kintz Samuel
(President and CEO) |
M | Common Stock | A | 8026 | $1.12 - $1.12 | $8,989 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |